Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403669 · ClinicalTrials.gov registry record · NA
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
A NA study of Heart Failure and Diabetes Mellitus, sponsored by Aventyn.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT07403669: Recruiting NA study of Heart Failure and Diabetes Mellitus, sponsored by Aventyn.
NCT07403669 is a NA study of Heart Failure and Diabetes Mellitus that is actively recruiting participants, run by Aventyn. The registered enrollment target is 300 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07403669, a NA study of Heart Failure and Diabetes Mellitus, is actively recruiting participants, sponsored by Aventyn.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Primary Outcome
Improvement of patient outcomes will be measured by reduction of composite of Kidney failure/progression of kidney disease, Heart failure, Acute Mi events and diabetes complications and hospitalization as well as all-cause mortality through 30 days, 90 days and 180 days in patients CKM
Conditions Studied
Interventions
- OTHER CHAPERONE AI
- DEVICE CKMiq AI
- OTHER Quality of Life
Study Locations (5)
Arizona
- Fountains Family Care - Chandler
- Gilbert Cardiology - Gilbert
- Arizona Heart Foundation - Phoenix
- East Valley Diabetes - San Tan Valley
Other
- Karolinska University Hospital - Stockholm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2027-04-22 |
| Phase | NA |
What NCT07403669 shows while recruiting
NCT07403669 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which CHAPERONE AI is the first listed.
NCT07403669 lists 5 locations in 2 states (Arizona, Other).
Frequently Asked Questions
What is clinical trial NCT07403669 about?
NCT07403669 is a clinical study titled "Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment". The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an alg...
What is the current status of trial NCT07403669?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-10-22. Estimated completion is 2027-04-22.
What conditions does trial NCT07403669 study?
This clinical trial studies the following conditions: Heart Failure, Diabetes Mellitus, Kidney Disease, Acute MI.
What interventions are being tested in trial NCT07403669?
The interventions under investigation include: CHAPERONE AI (OTHER), CKMiq AI (DEVICE), Quality of Life (OTHER).
Who is sponsoring clinical trial NCT07403669?
This trial is sponsored by Aventyn, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07403669 being conducted?
This trial has 5 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07403669's enrollment target sits among peer trials
300 138th of 397 higher than 253 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI